Live
- A Soulful Celebration of Global Music
- Brahmin Community delegation felicitates CM Saini
- Allu Arjun Visits Chiranjeevi’s House for Lunch Meet
- Toyota organising TG Grameena Mahotsav
- Special rituals conducted at Maramma Temple
- Siddaramaiah has special love for Muslims: BJP
- We can’t afford spending less than 6% of GDP on healthcare
- Guinness World Record for continuous Hanuman Chalisa chanting
- REMOTE TRIBAL AREA TO GET NEW BRIDGE
- Dr LB College, Woxsen teams win in Climate Tank Accelerator event
Breakthrough in dengue drug
In a breakthrough move that can help in the fight against dengue, a herbal medicine against it is claimed to have been developed by scientists in India, which accounts for 50 per cent of the global population estimated to be at risk from the disease.
New Delhi: In a breakthrough move that can help in the fight against dengue, a herbal medicine against it is claimed to have been developed by scientists in India, which accounts for 50 per cent of the global population estimated to be at risk from the disease.
Experts are now gearing up for the next step, which is to hold clinical trials and toxicity studies before seeking permission from the Ministry of Ayush and the Drug Controller of India (DCI) for commercial production.
The project was undertaken jointly by the Department of Biotechnology (DBT), under the Ministry of Science and Technology, the International Centre for Genetic Engineering and Biotechnology (IGCEB) and Ranbaxy Research Laboratory (now owned by Sun Pharma), and employed Ayurveda in devising the drug.
"Using the knowledge of traditional Indian medicine Ayurveda we developed a systematic bioassay-guided screening approach to explore the indigenous herbal bio- resource to identify plants with pan-DENV (dengue virus) inhibitory activity," said Navin Khanna, senior scientist at ICGEB and the group leader of the project.
"Results showed that the alcoholic extract of Cissampelos pariera Linn (Cipa extract) was a potent inhibitor of all four DENVs in cell-based assays, assessed in terms of viral NS1 antigen secretion using ELISA, as well as viral replication, based on plaque assays. Virus yield reduction assays showed that Cipa extract could decrease viral titers by an order of magnitude. The extract conferred statistically significant protection against DENV infection," he added.
He also added that preliminary evaluation of the clinical relevance of Cipa extract showed it had no adverse impact on platelet count and RBC viability. It also showed no evidence of toxicity in Wistar rats, when administered doses as high as two grams/kilogram body weight for up to a week. "We have tested it on rats and have got positive results, but now it needs to be tested on bigger animals," Khanna said.
